Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of HRS-6209 combination therapy in breast cancer
CTR20251838Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-6209 in breast cancer, sponsored by Hengrui Therapeutics. Started Jun 2025; status: active.
02
Drugs
HRS-6209
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20251838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251838.